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Abstract 
Background: Malaria remains a major public health problem, with half the world population at risk of contracting 
malaria. The effects of Plasmodium vivax on prosperity and longevity have been highlighted in several recent clinical 
case reports. The first line of vivax treatment drugs has seen no radical innovation for more than 60 years. This study 
introduces a subtle incremental innovation to vivax treatment: a chloroquine and primaquine co-blister. The co-blister 
includes a new chloroquine formulation incorporating coated tablets to mask the drug’s bitter taste and user-friendly 
packaging containing tablets of each drug, which may improve patient adherence and facilitate the appropriate use 
of the drugs. This new formulation will replace the non-coated chloroquine distributed in Brazil.
Methods: Patients were orally treated with 150 mg coated chloroquine tablets for 3 days: an initial 450 mg dose, 
followed by two 300 mg doses. The patients were treated concomitantly with two 15 mg primaquine tablets for 
7–9 days, according to their weight. The primary objective of this study was to prove parasitological and clinical cure 
rates above 90 % by day 28.
Results: This single-arm open-label non-comparative trial was conducted according to the WHO recommended meth-
odology for the surveillance of anti-malarial drug efficacy in the Brazilian Amazon. On day 28, the parasitological and clini-
cal response was adequate in 98.8 % of patients (CI 95 % 93.4–100 %). The success rate on day 3 was 100 %, and the cumu-
lative success rate by day 28 was 98.8 % (CI 95 % 91.7–99.8 %). There were no serious adverse events, with most adverse 
events classified as mild. The pharmacokinetic parameters of chloroquine analysed in whole blood dry spot samples 
showed mean (coefficient of variation) Cmax and AUC0–t values of 374.44 (0.35) and 3700.43 (0.36) ng/mL, respectively.
Discussion: This study reports an appropriate safety and efficacy profile of a new formulation of coated chloroquine 
tablets for vivax malaria treatment in the Brazilian Amazon. The cure rates meet the WHO efficacy criteria, supporting 
current Brazilian guidelines and the use of the formulation for vivax malaria treatment. Nevertheless, further studies 
should be conducted to address adherence and the effectiveness of the formulation.
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Background
Malaria remains a major public health problem. Despite 
many advances in the past 15 years, 3.2 billion people are 
at risk of contracting malaria, which represents half of 
the population of the world. According the World Health 
Organization (WHO), in its 2015 World Malaria Report, 
the number of malaria cases decreased from an estimated 
262 million in 2000 (range 205–316 million) to 214 million 
in 2015 (range 149–303 million), a decline of 18 % [1, 2].
Plasmodium falciparum has been the primary target 
of malaria drug development for the past 15  years. The 
high mortality, the emergence of drug resistance and 
the record high number of cases in Africa justify this 
approach. Although falciparum malaria is still a major 
public health problem, during the past decade, key 
achievements have dramatically changed its epidemio-
logical profile, such as new rapid diagnosis tests (RDT) 
and new treatments comprising fixed dose combinations 
of artemisinin derivatives and other anti-malarial drugs. 
In Brazil, the incidence ratio of falciparum/vivax has con-
siderably changed since artemisinin-based combination 
therapy (ACT) has been recommended as the first-line 
treatment. In 1988, Plasmodium vivax and P. falcipa-
rum had incidence rates of 50  % each. In 1990, P. falci-
parum corresponded to 44.3 % of cases; in 2009, 3 years 
after ACT implementation, P. vivax represented 84 % of 
the recorded cases, whereas P. falciparum represented 
only 16  % [3]. In 2014, 143,552 cases of malaria were 
reported. Although the falciparum/vivax ratio was not 
constant between the years of 2012 and 2013 [4], P. vivax 
infections accounted for 84 % of cases in 2014. The total 
number of cases declined by 19 % compared to 2013. The 
overall number of cases is currently the lowest it has been 
for the past 35 years in Brazil [5].
The importance of P. vivax has been highlighted based 
on its effects on prosperity and longevity [6, 7], and many 
severe and fatal clinical cases reports have been pub-
lished [8–13]. In 2014, P. vivax was the most frequent 
cause of hospitalization (63  %) and death (11/23) due 
to malaria in the Brazilian Amazon region [5]. In addi-
tion to new cases, 39,279 possible recurrence cases were 
reported in 2012 [4], among which the recurrences were 
due to re-infection, resistance or non-compliance to the 
treatment [14].
In addition, various barriers are known to impair trans-
mission control as the early appearance of gametocytes 
and relapses from hypnozoites. In 2009, Guerra et al. [15] 
estimated that 2.85 billion people were exposed a risk of 
vivax infection.
The first line drug treatment for vivax malaria has 
been used for more than 60 years with no radical inno-
vation. To address the lack of research progress on this 
most neglected disease [16], an incremental innovation 
to P. vivax treatment was developed in this study: a chlo-
roquine and primaquine co-blister. This approach is a 
formulation and packaging improvement of the current 
vivax treatment recommended by the Brazilian Ministry 
of Health. The co-blister of chloroquine and primaquine 
was developed assuming that a user-friendly primary 
package containing both tablets of concomitant use 
may improve adherence [17]. The co-blister preliminary 
design is provided in Additional file 1. Stratifying the pri-
mary package according patient age ranges may facilitate 
the appropriate use of the drugs [18] especially in the 
majority of drug distribution settings in Brazil where the 
drugs dispensers are communitarian health agents [19]. 
In Brazil, vivax treatment has five weight ranges, vary-
ing from 17 to 26 tablets in three different tablet con-
centrations. Although health agents may have their own 
prescription strategies, difficulties remain regarding 
ensuring the correct posology when ten loose tablets are 
prescribed, especially in households in which illiterate 
people reside or with more than one patient.
The new user-friendly primary polyvinylidene chloride 
(PVDC) package of coated chloroquine and primaquine 
may replace the non-coated chloroquine packed in paper 
strips that have been distributed in Brazil. The co-blister 
includes a new chloroquine formulation of coated tab-
lets. Coating the chloroquine masks the bitter taste of the 
drug and may improve treatment adherence. Although it 
was not studied in this population, bitter taste is known 
as a factor that may impair adherence [20]. In this study, 
the evaluation of improvements upon treatment was 
focused on the formulation rather than the dosing. The 
primary objective of this study was to prove parasitologi-
cal and clinical cure rates of the new formulation above 
90 % by day 28. This paper presents the safety and efficacy 
results of this new formulation. These results represent 
the first step towards the introduction of a user-friendly 
co-blister of chloroquine and primaquine to treat malaria 
vivax in Brazil. Nevertheless, further studies should be 
conducted to address adherence and effectiveness of the 
new chloroquine formulation and the co-blister.
Methods
Ethics and regulatory statement
The clinical study protocol and informed consent were 
reviewed and approved by the Ethics Committee at the 
Tropical Medicine Research Center of Rondônia (Nº 
01/11 CEP/CEPEM e Nº 0001.0.046.000-11 CAAE-
SISNEP). The Brazilian National Council on Ethics in 
Research (CONEP), Ministry of Health, accredits this 
committee. The clinical study was conducted in accord-
ance with the Helsinki Declaration, Good Clinical Prac-
tice [21] and the Brazilian National Health Council 
(CNS) resolutions 196/1996 and 466/2011. The study 
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is registered with the Brazilian Register of Clinical Tri-
als (RBR-77q7t3-UTN: U1111-1121-2982). The protocol 
was also approved by the National Regulatory Agency, 
ANVISA (CE No. 188/2012-0896111125), and this study 
was conducted according the Good Clinical Practice 
(GCP) [22]. During the study, visits were conducted to 
ensure GCP adherence. Written informed consent was 
obtained for every subject prior to enrolment. If the 
study subject was illiterate, an impartial third party wit-
nessed the informed consent process. All subjects were 
informed of the nature of the trial and the possible risks 
bound to it and that they were free to withdraw their 
consent to participate at any time. The investigators and 
study staff ensured confidentiality of all records.
Study population
Patients with vivax malaria mono-infection willing to 
participate were included in the study after signing the 
informed consent form if they met the following inclu-
sion criteria: aged between 18 and 70  years; weight 
between 50 and 90  kg, P. vivax infection confirmed by 
microscopy, asexual parasite count >250/μL; either axil-
lar temperature ≥37.5 °C or a history of fever during the 
past 48 h; the ability to swallow tablets; and the availabil-
ity to attend the study follow-up visits. Patients who met 
one of the following criteria were not eligible to partici-
pate: prior malaria treatment in the past 63 days; signs of 
severe malaria; either other febrile conditions or chronic 
disease (such as severe cardiac, hepatic or renal disorders 
and AIDS); the use of any medication that interferes with 
anti-malarial pharmacokinetics; an intolerance to chlo-
roquine or primaquine; a known glucose-6-phosphate 
deficiency; pregnancy confirmed by human chorionic 
gonadotropin (hCG) in their urine or breastfeeding; or 
among the indigenous population.
Study design and drug administration procedures
This single arm open-label non-comparative trial was 
conducted according the WHO recommendations [23] 
at the Tropical Medicine Research Centre of Rondônia 
(CEPEM). This centre is located in the Amazon Region 
of Brazil. The demonstration of at least a 90 % cure rate 
is considered by the WHO to be satisfactory evidence 
of efficacy to support the National Malaria Control Pro-
gramme treatment guidelines [23]. The sample size was 
calculated with an expected failure rate of 5 %. To achieve 
a precision level of 5 % and a possible loss of 20 % of par-
ticipants by the follow-up, 88 patients were included.
Eligible patients were treated in accordance with the 
Brazilian Ministry of Health recommendation [24]. All 
patients who were included were orally treated with 
150  mg coated chloroquine tablets (Farmanguinhos— 
Fiocruz, batch number 11090655) for 3  days. On the 
first day, a higher dose of chloroquine was administered 
(450  mg) followed by 2  days of 300  mg doses per day. 
Patients were also concomitantly treated with two tablets 
of primaquine 15  mg (Farmanguinhos—Fiocruz, batch 
numbers 12010038; 13030282) for 7, 8 or 9 days according 
three weight ranges (≥50–69; 70–79; 80–90  kg), respec-
tively. The total primaquine dose was never lower than 
3 mg/kg or higher than 4.2 mg/kg. An illustrative table is 
provided as an additional file (Additional file 2).
Chloroquine and primaquine administrations were 
supervised during the first 3 days. The first dose was taken 
after diagnosis, and the following doses were adminis-
tered between 8 and 10 a.m. If the patient vomited within 
30 min after a dose, the same dose was administered again. 
Treatment adherence to primaquine between days 4 and 
7 was assessed by inquiring with the patients at the day 7 
follow-up visit. The patients were also asked about the use 
of concomitant therapies at every visit and recorded.
Safety and efficacy evaluations
Patients were evaluated on the day of enrolment and on 
days 1, 2, 3, 7, 14, 21 and 28 after the study period. The 
scheduled study procedures included a complete clinical 
anamnesis, a physical exam and a urinalysis at enrolment 
and an assessment of the most frequent clinical signs of 
malaria and adverse events (AEs) at all the follow-up vis-
its. Additionally, blood samples were collected for para-
site counts (0, 2, 3, 7, 14, 21 and 28 days), haemoglobin 
and haematocrit evaluations (0, 14 and 28 days), genotyp-
ing (0, 7, 14, 21 and 28  days) and chloroquine pharma-
cokinetic analyses (0, 3, 7, 14, 21 and 28 days).
The primary efficacy endpoint was the proportion of 
the population with an adequate clinical and parasitolog-
ical response; otherwise, it was classified either as early 
treatment failure or late treatment failure.
Both per protocol (PP) and intention-to-treat (ITT) 
analyses were conducted, for which the PP was the pri-
mary analysis, and the ITT analysis was performed to 
confirm the results. The PP population excluded any par-
ticipant associated with a protocol violation or who was 
lost by the follow-up visit at the primary endpoint on day 
28, whereas the ITT population included any violation or 
loss by the follow-up as parasitological and clinical fail-
ure. The cumulative success rate by day 28, correspond-
ing to the probability of remaining parasite-free at day 
28, was calculated using a Kaplan Meyer survival curve. 
The absolute number of patients who presented symp-
toms and parasitaemia 72 h after treatment were defined 
as early treatment failures. Demographic data were 
presented for both populations. All the data were sum-
marized as frequencies and percentages for categorical 
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variables and as the means  ±  standard deviations (SD) 
for quantitative variables.
The safety analysis was conducted in the ITT population 
describing the frequency of AEs and stratifying the AEs 
among the follow categories: serious AEs, AEs leading to 
treatment suspension, and AEs corresponding to causali-
ties described as doubtful, unlikely, possible or probable. 
The mean haemoglobin and haematocrit results at base-
line and at the follow-up visits are also presented.
The patients were encouraged to seek unscheduled 
assessments if any AE was suspected. All clinical or labo-
ratory abnormalities were categorized as grade I to IV 
according to the common terminology criteria for adverse 
events (CTCAE) of the National Cancer Institute [25]. Any 
suspected serious AE as defined by good clinical practice 
was reported to the sponsor and the Ethical Review Com-
mittee. Any disorder recorded at the inclusion anamne-
sis or the recurrence of the disorder were not recorded as 
an AE. However, any exacerbation of a previous disorder, 
either in frequency or intensity, was described as an AE. 
Known drug-related events were recorded as an AE, even if 
it could be classified as a malaria symptom.
The parasitological densities were estimated using 
Giemsa-stained blood slides at a magnification of 1000× 
as the WHO recommended methodology for the sur-
veillance of anti-malarial drug efficacy [23]. Two trained 
microscopists provided independent results, and the 
final densities corresponded to the average of the two 
independent assessments. A third microscopist evalu-
ated discordant results pertaining to the presence or 
absence of parasites, the diagnosis of different species, or 
the report of a parasite density greater than 50 % in the 
same slide. In this case, the final densities corresponded 
to the average of the two closest counts. Negative results 
were issued only after the evaluation of 1000 leucocytes 
in the microscopic fields. Gametocyte presence was also 
recorded. Genotyping samples were not collected to cor-
rect results by PCR, as a high frequency of heterologous 
hypnozoite activation during vivax relapse is known [26].
To access chloroquine pharmacokinetics, samples of 
the peripheral blood were collected either at domicili-
ary visits or at the day of a clinic visit and transferred to 
Whatman (USA) ET 31 CHR E 3MM filter papers. The 
whole blood concentrations of chloroquine were meas-
ured using validated high performance liquid chroma-
tography tandem to a mass spectrometry (HPLC–MS/
MS) method. This method was in accordance with Bra-
zilian [27] and international [28] regulatory require-
ments for bioanalytical methods. The pharmacokinetics 
laboratorial analysis was conducted at the Sefar/Oswaldo 
Cruz Foundation, which is accredited by the Brazilian 
regulatory agency, ANVISA. The main pharmacokinetic 
parameters of Cmax, Tmax, AUC0–t and AUC0–inf were 
calculated using the software WinNonlinTM version 6.3 
Pharsight and Microsoft Excel version 14.4.0. The pres-
ence of parasites with chloroquine blood levels above 
the 100 ng/mL threshold was considered to characterize 
resistance according the protocol and the WHO.
Results
Baseline characteristics of the study population
A total of 921 patients were screened at the Tropical 
Medicine Research Centre of Rondônia, Porto Velho, 
Brazil from April 2013 to April 2015. Eighty-eight 
patients who met all inclusion criteria were enrolled in 
the study. Patients were excluded from the study if they 
were unavailable to attend the study follow-up visits, 
resided in a remote area (41.7  %), had been adminis-
tered malaria treatment within the past 63 days (21.4 %), 
weighted >90  kg (9.2  %), were already participating in 
another clinical trial (7.1 %), had a P. falciparum infection 
(3.8 %), were less than 18 years of age (2.5 %), contracted 
either other febrile condition or chronic disease (1  %), 
declined to participate (1  %), were over 70  years of age 
(0.4 %), or another justifiable reason (1.6 %). A flow chart 
is provided in Additional file 3.
Among the 88 enrolled patients, 82 (93.2  %) finished 
the follow-up and were included in the PP analysis. One 
patient withdrew the informed consent (1.1 %). Protocol 
deviations included one P. falciparum infected patient 
(1.1 %) and one malaria mixed infection patient (1.1 %). 
Three patients were lost by the follow-up visit (3.5 %). All 
88 patients were included the ITT efficacy analysis and 
safety analysis. Qualitative and quantitative demographic 
population characteristics and the clinical baseline of the 
PP and ITT populations are presented in Tables 1 and 2.
The most frequent symptoms at enrolment were fever 
(98.7  %), myalgia (90.9  %), chills (89.8  %) and headache 
(86.4 %). The concomitant treatments most reported prior 
to enrolment were administration of antipyretics/analgesics 
(46.6 %), antihypertensive agents (3.4 %) and antihistamines 
(2.3  %). After study initiation, 73.3  % of the population 
reported the administration of concomitant medications. 
Most of these patients took a symptomatic treatment two 
or three times. Non-steroidal anti-inflammatory drugs 
(NSAIDs) were the drugs most frequently reported con-
comitant medication (50.3 %). NSAIDs and antihistamines 
were often taken within the first 3 days after anti-malarial 
treatment initiation, which may be due to either to malaria 
symptoms or to chloroquine-related pruritus.
All treatment doses with the new chloroquine formu-
lation and primaquine were supervised during the ini-
tial 3 days. Patients were asked about their adherence to 
the primaquine doses at the day 7 follow-up visit. Two 
patients (2.3 %) reported disruption of primaquine treat-
ment either on day 4 or 5 but neither were classified as a 
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treatment failure. Therefore, these patients were included 
in the PP analysis.
Efficacy results
Among the 82 patients in the PP population, parasito-
logical and clinical responses were adequate in 98.8  % 
(CI 95 % 93.4–100). There was one failure at day 29; how-
ever, because the protocol allows a 1-day margin for this 
follow-up visit, this patient was considered a late clinical 
and parasitological failure.
Secondary endpoints included the cure rate at day 3 (or 
early parasitological failure rate) and the cumulative suc-
cess rate at day 28 based on the survival Kaplan–Meyer 
method. Early parasitological clearance 72  h after treat-
ment initiation was evaluated in 84 patients. The success 
rate at day 3 was 100  %. The cumulative success rate at 
day 28 or the probability of remaining parasite-free at day 
28 was 98.8 % (CI 95 % 91.7–99.8).
Safety results
There were no deaths in this study, nor any other serious 
adverse event, as defined by GCP. No AEs led to treat-
ment suspension. A safety analysis was conducted for the 
ITT population, as all patients received at least three days 
of chloroquine and primaquine.
A total of 380 AEs were reported during the study. The 
principal investigator described 304 (80 %) AEs as grade 
I, 74 AEs (19.7  %) as grade II, and only one (0.3  %) AE 
as grade III. There was no report of a grade IV AE. The 
number of AEs and their distribution according to the 
type of casualty are given in Table 3.
Among the 214 (56.3  %) AEs classified as possibly 
related to the test drugs, 186 (48.9 %) were classified as 
grade I and 28 (7.4 %) as grade II. None of the grade III or 
grade IV AEs were classified as possibly related to the test 
drugs. There were 82 (21.6 %) events likely related to the 
test drugs, of which 61 (16.0 %) were classified as grade 
I, and 21 (5.5 %) as grade II; none were reported as grade 
III or grade IV. Among the 296 events possibly or likely 
related to the test drugs, 247 (83.4 %) were classified as 
grade I and, therefore, did not require any treatment.
The most frequent AEs were pruritus (56 %), headache 
(38.6 %), abdominal pain (35.2 %), sleep disorder (31.8 %), 
nauseas (28.4  %), diarrhoea (20.5  %). Vomiting, lack of 
appetite, cutaneous rash, muscular pain, compartmental 
disorder, and dizziness were reported in more than 5 % 
of the population. Thirty-nine patients (44.3 %) reported 
Table 1 Demographic population characteristics and  the 
clinical baseline data of the PP and ITT populations—cat-
egorical variables
Categorical variables Absolute number and percent-
age (%)
ITT population PP population
Total number of patients IT = 88 (100) PP = 82 (100)
Gender
 Male 67 (76.1) 61 (74.4)
 Female 21(23.8) 21 (25.6)
Age (years)
 18–39 53 (60.2) 48 (58.50)
 40–59 33 (37.5) 32 (39.0)
 60–70 2 (2.3) 2 (2.5)
Weight (kg)
 >50–69 41 (46.6) 39 (47.6)
 70–79 27 (30.7) 24 (29.3)
 80–90 20 (22.7) 19 (23.2)
Previous malaria
 Yes 76 (86.4) 71 (86.6)
Number of previous malaria episodes
 Zero 12 (13.7) 11 (13.4)
 1–5 41 (46.6) 39 (47.6)
 6–10 15 (17.0) 14 (17.1)
 >10 17 (19.3) 15 (18.3)
 Not known 3 (3.4) 3 (3.7)
Fever during exam
 Yes 33 (37.5) 32 (39.0)
Table 2 Demographic population characteristics and the clinical baseline data of the PP and ITT populations—quantita-
tive variables
ITT PP
Mean (SD) Range Mean (SD) Range
Weight (kg) 70.7 (11.3) 52–90 70.7 (10.7) 51–90
Temperature (oC) 37.8 (1.4) 35–42 37.8 (1.4) 35–42
Parasitemia (μL) 2360 282–12,000 3353.7 282–12,000
Age (years) 38.4 (10.9) 19.3–68.6 38.2 19–68
Systolic arterial pressure (mmHg) 113 (13.2) 90–150 112.9 (13.2) 90–150
Diastolic arterial pressure (mmHg) 71.9 (9.3) 50–100 71.8 (9.6) 50–100
Number of days with symptoms prior to treatment (n = 76) 3.7 (2.2) 1–15 3.8 (2.3) 1–15
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AEs that were classified as doubtfully related to the study 
drugs. AEs possibly related to the drugs were observed in 
64 (72.7 %) patients, and AEs likely related to the medica-
tion were described in 49 (55.7 %) patients. A total of 74 
(84 %) patients reported either an AE possibly related to 
or an AE likely related to the study drugs.
The distribution of AEs according the main body sys-
tem disorders and the follow-up visit interval is presented 
in Fig. 1. The frequency of all AEs sharply decreased after 
the third day of treatment, and further reductions were 
described afterwards. The only exception was the fre-
quency of headaches, which slightly increased between 
the 14th and 30th days. Details of the AE counts reported 
per day are provided in Additional file 4.
A similar pattern was observed for the time to dis-
appearance of symptoms. Fevers were recorded in 87 
(98.9 %) patients at the time of enrolment and were pre-
sent in 4 (4.5 %) patients at day 3. At the time of enrol-
ment, 48 and 40 patients reported nausea and abdominal 
pain, respectively. At day 1, there was a 92.4 % decrease 
in reported nausea and a 68.7  % decrease in reported 
abdominal pain. As these symptoms are related to both 
the disease and treatment, they were recorded as AEs 
if they were not present prior to administration or they 
were recurrent. This overlap in symptoms may have led 
to an over estimation of AEs; however, it provides a con-
servative safety profile.
The mean haematocrit and haemoglobin on days 0, 14 
and 28 are presented in the Table 4 and Fig. 2. Although 
the p value was statistically significant, the variation was 
not clinically relevant.
Pharmacokinetics results
The pharmacokinetic parameters of chloroquine in whole 
blood dry spot samples (n =  86 patients) are presented 
with the mean, standard deviation, coefficient of varia-
tion, and minimum and maximum values in Table 5. Fig-
ure 3 demonstrates the mean concentrations during the 
study.
All patients achieved whole blood levels above 100  ng/
mL. The minimum value at Cmax was 122.20  ng/mL. 
The lowest value did not correspond to the patient who 
exhibited a clinical and parasitological failure at day 29. 
This patient maintained chloroquine blood levels above 
the minimum effective blood concentration until day 14. 
However, the sample collected on the failure day contained 
a lower concentration than 100 ng/mL and, therefore, does 
not characterize a resistant parasite according the proto-
col and the WHO. The coefficients of variation of the main 
pharmacokinetic parameters were high (≥0.35), which 
might be due to the restricted (6) sample of collection 
points.
Discussion
Despite the many achievements in malaria control over 
the past 15 years, malaria remains a major public health 
problem [1]. The 18  % worldwide incidence reduction 
trend observed in 2014 in comparison to 2013 [1] is simi-
lar to the 19 % reduction rate in Brazil observed during 
the same period. In 2014, Brazil achieved the lowest inci-
dence of malaria of the past 35 years [5]. Although pro-
gress towards falciparum elimination now represents a 
realizable goal that could not be foreseen 10  years ago, 
malaria vivax control is a more problematic issue. Vivax 
control also requires eliminating the appearance of early 
gametocytes and treatment of the extensive population 
of asymptomatic patients. The development of a new 
drug for the treatment of malaria vivax has been a known 
unmet need for many years, yet the primary first line of 
therapy has remained the same for the past 60  years in 
the vast majority of countries worldwide [16]. In this sce-
nario, known interventions for improving the safe and 
effective use of medicine [29] may represent an additional 
viable strategy for controlling malaria. The proposed 
chloroquine–primaquine co-blister represents a sub-
tle incremental technology that may markedly increase 
treatment adherence, thus eventually leading to reduced 
relapse rate, increased effectiveness and decreased trans-
mission. If this intervention decreases the time to relapse, 
it would greatly improve the patients’ quality of life. The 
availability of the new packaging is pending regulatory 
submission and approvals.
This study presents the safety and efficacy results of 
a new coated chloroquine formulation; nevertheless, 
Table 3 The number of AEs and their distribution according to the type of causality
Grade Causality
Total adverse events = 380 (%)
Doubtful Unlikely Possible Probable/likely Total
I 56 (14.7) 1 (0.3) 186 (48.9) 61 (16.1) 304 (80.0)
II 25 (6.6) 1 (0.3) 28 (7.4) 21 (5.5) 75 (19.7)
III 1 (0.3) 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.3)
Total 82 (21.6) 2 (0.5) 214 (56.3) 82 (21.6) 380 (100.0)
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improving adherence, acceptability and suitability to local 
needs and behaviours remain clear limitations of malaria 
treatment, and the effectiveness for which have not yet 
been evaluated and remain to be proven. Further studies 
to are currently planned to provide this lack of data and to 
increase the body of evidence supporting innovative and 
simple approaches to improve public health. Additional 
pharmaceutical developments must also be pursued to 
address the need of children who cannot swallow tablets.
The efficacy results reported here are comparable to 
other recent publications in Brazil [30]. Although the 
efficacy was adequate at 28 days, as recommended by the 
WHO [23], this follow-up period may not provide the 
best sensitivity for evaluating vivax relapse in the clinical 
trial in Brazil. Further studies are ongoing and may shed 
light on a better time performing follow-up evaluations in 
malaria vivax trials. The single patient who was classified 
as a failure was a 29-year-old male weighting 68.4 kg with 
no comorbidities, low parasitaemia at day 0 (450  para-
sites/dL) and no parasites on day 2. Furthermore, his 
most recent malarial infection was due to P. vivax more 
than 1  year prior to this study, and he reported adher-
ence to the primaquine treatment. The pharmacokinetic 
analysis revealed the chloroquine exposure in this patient 
that was similar to the other patients. The drug levels 
on the day of failure did not characterize the parasite as 
Fig. 1 Distribution of AEs per body system disorders and follow-up visit intervals
Table 4 Median haematocrit and haemoglobin on days 0, 14, and 28
Laboratorial result Day 0 (n = 87) Day 14 (n = 82) Day 28 (n = 81)
Median Range (SD) Median Range (SD) Median Range (SD)
Haemoglobin 13.7 8.6–16.8 (1.5) 13.0 9.6–16.3 (1.3) 13.8 11.4–16.5 (1.1)
Haematocrit 41.1 27.8–51.5 (4.8) 39.9 32.0–48.6 (3.7) 42.2 35.8–51.5 (3.3)
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resistant. Due to the one single failure, the known high 
frequency of heterologous hypnozoite activation during a 
vivax relapse, and the lack of access to deep sequencing at 
the end of this study, genotyping to differentiate relapse 
from possible re-infection was not conducted.
In an endemic area, the probability of remaining par-
asite-free as long as possible is a relevant measure that 
contributes to patient quality of life. At day 28, the prob-
ability of the patients being parasite-free was 98.8  % in 
this trial. The treatments were directly observed during 
the first 3  days, and primaquine doses were continually 
adjusted per kilogram. A limitation of this study is high-
lighted by the fact that the initial 3  days of treatment 
were directly observed in this clinical trial setting, which 
is unlike routine health assistance in this area and may 
compromise the external validity of this study. On the 
other hand, primaquine administration was not super-
vised after day 3, and therefore, the actual efficacy of the 
results as to whether they represent the complete recom-
mended treatment may be challenged.
Fig. 2 Box plots of the median haemoglobin on days 0, 14 and 28
Table 5 Chloroquine pharmacokinetic parameters (n = 86)
Cmax Tmax AUC0–t AUC0–inf Vd Cl
ng/mL Days Days (ng/mL) Days (ng/mL) mg/(ng/mL) mg/days (ng/mL)
Mean 374.66 27.51 3700.43 3949.30 0.49 0.04
SD 129.57 2.09 1394.43 1431.95 0.34 0.02
CV 0.35 0.08 0.38 0.36 0.69 0.50
Minimum 122.10 14.0 690.60 826.84 0.16 0.02
Maximum 733.52 28.0 8045.24 9331.73 2.74 0.18
Fig. 3 Curve of the blood concentration of chloroquine versus time
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Many AEs were reported in the safety results, highlight-
ing the awareness of the study team regarding the impor-
tance of the patients’ safety profiles in a study associated 
with regulatory processes. Most of the AEs were mild and 
did not require any symptomatic treatment. The safety 
profile concerned treatment adherence, although it is simi-
lar to that described in literature. A review of primaquine 
clinical trials including safety evaluations from 11,466 
patients reported a rate of serious AEs of 8.7 per 10,000 
and no deaths [31]. Although chloroquine can be used for 
many therapeutic indications other than malaria, the AEs 
that occurred at a rate higher than 5 % included pruritus, 
headache, gastro-intestinal discomfort, and central nerv-
ous system (CNS) disorders [32]. Nevertheless, as the sam-
ple size was small and there was not a group comparison, 
the safety evaluation was limited. However, as the primary 
change in the malaria treatment was related to the formu-
lation rather than the dosing, it can be concluded that the 
treatment is safe in the dose range and population studied.
Conclusion
This study shows the safety and efficacy of a new formu-
lation of coated chloroquine for vivax malaria treatment 
in Brazil. The cure rate was 98.8 % (CI 95 % 93.4–100 %) 
and met the WHO criteria. This study provides satisfac-
tory evidence of the efficacy of the formulation, support-
ing the National Malaria Control Programme treatment 
guidelines. The treatment is also safe in the dose range 
and population studied. There is no evidence of P. vivax 
resistance to the treatment in the study population. These 
results support the use of a new formulation of coated 
chloroquine tablets in Brazil and may be the first step 
towards a user-friendly co-blister of chloroquine and pri-
maquine to treat malaria vivax.
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